Intra-Cellular fingers a high placebo response explaining a PhIII failure as lead drug goes 1-and-1 in depression
Intra-Cellular Therapies put its best foot forward this morning, highlighting the positive impact its drug lumateperone had in a pivotal study of bipolar depression. But as we’ve seen so many times before in Phase III depression research, the Phase III running alongside the winning study failed to show any real improvement over a sugar pill — scrambling the outcome with a mixed set of data that leaves this program under a cloud.
The biotech’s shares $ITCI were quickly dragged lower Monday morning, but not in a disastrous fashion. And as we’ve learned from J&J’s esketamine work, a Phase III failure doesn’t necessarily act as a harbinger of doom.
Basic subscription required
Unlock this story instantly and join 55,100+ biopharma pros reading Endpoints daily — and it's free.